2nd Quarter - Report

SHIRE PHARMACEUTICALS LLC for SHIRE PHARMACEUTICALS LLC

Firm
Client
Income
—
Expenses
$320,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

ADHD awareness Binge Eating Disorder awareness Newborn Screening DEA processes and re-exportation FDA funding Medicare Chronic Care Reform Medicaid line extension rebates Medicaid rare disease patient access to therapy Orphan drug tax credit Orphan Drug Act regulations H.R. 6, 21st Century Cures Act, including expanded access, rare pediatric disease priority review vouchers re-authorization, DEA re-exports, OPEN Act, NIH funding, and exclusion of authorized generics from AMP calculations Expanded Access, including H.R. 909, Andrea Sloan Compassionate Use Reform and Enhancement Act and S. 2912, Trickett Wendler Right to Try Act of 2016 Advancing Hope Act of 2015 (S. 1878, H.R. 1537) ; related to rare pediatric disease priority review vouchers Anna Westin Act of 2015 (H.R. 2515, S. 1865) Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015 (H.R. 971, S. 1421)

LobbyistCovered position, as disclosed
EDWARD BUCKLEY —
JOHN EDWARD GREISSING —
MARK LENKER —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 909 (114th), H.R. 6 (114th), S. 1865 (114th), S. 1878 (114th), H.R. 1537 (114th), H.R. 2515 (114th), S. 2912 (114th), H.R. 971 (114th), S. 1421 (114th)

Health Issues HCR

H.R. 6, the 21st Century Cures Act: To accelerate the discovery, development, and delivery of 21st century cures, and for other purposes. 340B Drug Discount Program Orphan Drug Act Biosimilars Gene Therapy Drug Pricing ____________________________________ Titles: S.2689 - 114th Congress (2015-2016) Short Titles: Short Titles - Senate Short Titles as Introduced: REGROW Act Reliable and Effective Growth for Regenerative Health Options that Improve Wellness Official Titles: Official Titles - Senate Official Titles as Introduced: A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to cellular therapies.

LobbyistCovered position, as disclosed
ENGEL BURNS —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 2689 (114th), H.R. 6 (114th)

Medicare/Medicaid MMM

S. 275/HR. 605: Medicare Home Infusion Site of Care Act of 2015 Amends title XVIII (Medicare) of the Social Security Act to authorize Medicare coverage of home infusion therapy and home infusion drugs. Directs the Secretary of Health and Human Services to implement the Medicare home infusion therapy benefit in a manner that ensures that: (1) Medicare beneficiaries have timely and appropriate access to infusion therapy in their homes, and (2) there is rapid and seamless coordination between drug coverage under Medicare part D (Voluntary Prescription Drug Benefit Program) and home infusion therapy services coverage under Medicare part B (Supplemental Security Income) (SSI) to avoid the filing of duplicative or otherwise improper claims. Medicare coverage and reimbursement Medicare Part B drug payment model demonstration

LobbyistCovered position, as disclosed
ENGEL BURNS —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 275 (114th), H.R. 605 (114th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.